Pagnoux Christian, Guillevin Loïc
Division of Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Expert Rev Clin Immunol. 2015 Mar;11(3):339-48. doi: 10.1586/1744666X.2015.1008455. Epub 2015 Feb 2.
Granulomatosis with polyangiitis is a systemic necrotizing vasculitis characterized by granulomatous inflammation of small vessels and is associated with autoantibodies to neutrophil cytoplasmic proteases, mainly proteinase 3. Potentially lethal if not promptly diagnosed and treated, most patients with granulomatosis with polyangiitis can achieve remission with the current treatment modalities, with fewer side effects compared to three decades ago. However, the risk of relapse remains high, necessitating prolonged maintenance immunosuppressive therapy whose optimal duration remains undetermined. We review herein the treatment modalities for granulomatosis with polyangiitis and how they have evolved over the past decades. The findings of the most important and recently completed therapeutic studies, including on rituximab for maintenance, are summarized, before describing the main ongoing studies aimed at further optimizing treatment strategies.
肉芽肿性多血管炎是一种系统性坏死性血管炎,其特征为小血管的肉芽肿性炎症,并与抗中性粒细胞胞质蛋白酶自身抗体相关,主要是抗蛋白酶3抗体。若不及时诊断和治疗,肉芽肿性多血管炎可能致命,目前大多数肉芽肿性多血管炎患者通过现有治疗方式可实现缓解,与三十年前相比副作用更少。然而,复发风险仍然很高,需要长期维持免疫抑制治疗,而最佳疗程仍未确定。我们在此回顾肉芽肿性多血管炎的治疗方式及其在过去几十年中的演变。在描述旨在进一步优化治疗策略的主要正在进行的研究之前,总结了最重要且最近完成的治疗研究结果,包括有关利妥昔单抗维持治疗的研究结果。